Day: November 13, 2020

– Significant mean reduction of 26.5% in LDL-C with bempedoic acid vs. placebo in pooled analysis of people who cannot tolerate statins1–– Analysis by sex showed bempedoic acid significantly lowered LDL-C at week 12 in males and females* vs. placebo2–ANN ARBOR, Mich., Nov. 13, 2020 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced results of pooled data from four of the company’s Phase 3 trials were presented at the virtual American Heart Association Scientific Sessions 2020 (AHA 2020). Both analyses demonstrated significant lowering of low-density lipoprotein cholesterol (LDL-C) by NEXLETOL® (bempedoic acid) Tablets by week 12 in specific subgroups, including people who cannot tolerate statins and females, compared to placebo.     “Women are half of the population, and nearly 10 million patients...

NEWARK, N.J., Nov. 13, 2020 (GLOBE NEWSWIRE) — Esports Entertainment Group, Inc. (NasdaqCM: GMBL, GMBLW) (or the “Company”), a licensed online gambling company with a focus on esports wagering and 18+ gaming, will host a conference call and webcast on Monday, November 16, 2020 at 4:30 p.m. ET to answer questions about the Company’s operational and financial highlights for the third quarter of 2020 and recent developments.For interested individuals unable to join the conference call, a dial-in replay of the call will be available until November 30, 2020 and can be accessed by dialing +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International) and entering replay pin number: 10011948.About Esports Entertainment GroupEsports Entertainment Group, Inc. is a licensed online gambling company with a specific focus on esports...

AUSTIN, Texas, Nov. 13, 2020 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the pricing of its previously announced underwritten public offering. The Company is offering 9,375,000 shares of its common stock, par value $0.001 per share, at a price to the public of $8.00 per share. In connection with the offering, the Company has also granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock offered in the public offering.Cantor Fitzgerald & Co. is acting as lead bookrunning manager for the offering. H.C. Wainwright & Co. is acting as joint bookrunning manager for the offering. Maxim Group LLC is acting as a co-manager for the offering.The...

Company annoucement nr. 47Fredericia, November 13th. 2020Board member Jes Nordentoft, has chosen to resign from the board per. 25.11.2020.About Waturu Holding A/SWaturu Holding A/S is a Greentech company, which develops innovative water technology for heating ortreating water, with the focus on ensuring bacteria-free water and reducing water and energy consumptionfor heating hot water in properties and thus ensuring CO2 savings. Waturu Holding A/S is a majorshareholder in the medical company Watgen Medical A/S and in the technology company Aquaturu A/S.Further information:CEO Toke Reedtz, cell.: +45 5188 1262, e-mail: toke@waturu.comWaturu Holding A/SSjællandsgade 327100 VejleFinancial reports:www.waturu.com/documentsFurther press related news:www.linkedin.com/company/waturu/www.facebook.com/WaturuDenmark/

Selskabsmeddelelse nr. 47Fredericia, den 13. november 2020Bestyrelsesmedlem Jes Nordentoft, har valgt at udtræde af bestyrelsen pr. 25.11.2020.Om Waturu Holding A/SWaturu Holding A/S er en Greentech-virksomhed, som udvikler innovativ vandteknologi til opvarmningeller behandling af vand, med det fokus at sikre bakteriefrit vand samt nedsætte vand- og energiforbrugettil opvarmning af varmt brugsvand i ejendomme og dermed sikre CO2- besparelser. Waturu Holding A/S erhovedaktionær i medico selskabet Watgen Medical A/S samt i teknologiselskabet Aquaturu A/S.Vigtige links:www.waturu.dkwww.aquaturu.com www.watgenmedical.com 

In accordance with Article 19 of the Market Abuse Regulation, Gabriel Holding A/S publishes the following transaction.AttachmentGabriel Holding AS – Announcement no 15 Managers Transaction

I henhold til Markedsmisbrugsforordningen art. 19 offentliggør Gabriel Holding A/S følgende transaktion.Vedhæftet filGabriel Holding AS – Meddelelse nr. 15 – transaktion ledende medarbejder

VANCOUVER, British Columbia, Nov. 13, 2020 (GLOBE NEWSWIRE) — EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company”) announced today that it has signed an Equipment Purchase Agreement (the “Agreement”) with GEA Lyophil GmbH (“GEA”) to deliver a lab-scale Radiant Energy Vacuum (“REV™”) machine for the demonstration and development of REV™ technology for pharmaceutical applications.GEA will use the equipment to advance the commercialization of the technology for pharmaceutical applications. The lab-scale machine will be made available for trials with prospective pharma-industry purchasers of large-scale microwave-assisted lyophilization equipment. This machine will also be used for internal evaluation and technology advancement activities at GEA. This will allow GEA to better showcase EnWave’s technology to pharmaceutical...